Investor Presentaiton
INVESTMENT HIGHLIGHTS
Q Retina Focus - Alimera is a company committed to improving
the retinal health of patients through long-term treatment of
chronic diseases
Better Mousetrap – ILUVIEN and YUTIQ (acquired May 2023)
assets treat diabetic macular edema and non-infectious
uveitis affecting the posterior segment of the eye; only long-
term durable therapies available to reduce disease recurrence
through extended disease control
QPositioned for Profitable Growth - Recent acquisition
establishes critical mass for growth and profitability; over $100
million in revenue and $20 million in adjusted EBITDA
expected in 2024
Leverageable Global Infrastructure - Commercial presence
across 21 countries provides significant leverage for future
label expansion opportunities
Q Major Upcoming Milestones - Ongoing clinical trials with
readouts in 2024 and 2025 to provide additional data and
accelerate utilization
Nasdaq: ALIM
alimera
18View entire presentation